(Q45885397)

17 December 2017

title

Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study (English)

1 reference

17 December 2017

0 references

0 references

Pier Mannuccio Mannucci

8

object named as

Pier Mannuccio Mannucci

1 reference

17 December 2017

Elena Santagostino

1

1 reference

17 December 2017

Maria Elisa Mancuso

2

1 reference

17 December 2017

Angiola Rocino

3

1 reference

17 December 2017

Giacomo Mancuso

4

1 reference

17 December 2017

Maria Gabriella Mazzucconi

5

1 reference

17 December 2017

Annarita Tagliaferri

6

1 reference

17 December 2017

Maria Messina

7

1 reference

17 December 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

17 December 2017

British Journal of Haematology

published in

1 reference

17 December 2017

volume

130

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

422-427

1 reference

17 December 2017

Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

The factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Breastfeeding does not influence the development of inhibitors in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Environmental and genetic factors influencing inhibitor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Central venous access devices in haemophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

Oral immune tolerance induction to factor VIII via breast milk, a possibility?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2005.05605.X

10.1111/J.1365-2141.2005.05605.X

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

release_xujluz6qina6vj3ztglwi3rnoq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xujluz6qina6vj3ztglwi3rnoq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

17 December 2017